ORIC
Price
$13.63
Change
-$0.22 (-1.59%)
Updated
Oct 22 closing price
Capitalization
1.41B
21 days until earnings call
Intraday BUY SELL Signals
ZLAB
Price
$22.04
Change
-$2.16 (-8.93%)
Updated
Oct 22 closing price
Capitalization
2.47B
14 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ORIC vs ZLAB

ORIC vs ZLAB Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ORIC vs. ZLAB commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORIC is a StrongBuy and ZLAB is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ORIC with price predictions
Oct 22, 2026

ORIC in upward trend: price rose above 50-day moving average on October 20, 2026

ORIC moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 34 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ORIC's RSI Indicator exited the oversold zone, 34 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ORIC as a result. In 64 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.

The Moving Average Convergence Divergence (MACD) for ORIC just turned positive on October 19, 2026. Looking at past instances where ORIC's MACD turned positive, the stock continued to rise in 36 of 42 cases over the following month. The odds of a continued upward trend are 86%.

Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORIC advanced for three days, in 214 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for ORIC crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORIC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

ORIC broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ORIC entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.706) is normal, around the industry mean (2.973). P/E Ratio (-10.485) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ORIC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ORIC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for ZLAB with price predictions
Oct 22, 2026

ZLAB's RSI Indicator ascending out of oversold territory

The RSI Indicator for ZLAB moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 31 of the 37 cases the stock moved higher. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 59 cases where ZLAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +8.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in 201 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

ZLAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZLAB as a result. In 63 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

ZLAB moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ZLAB crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for ZLAB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.076) is normal, around the industry mean (2.973). P/E Ratio (-12.965) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (6.079) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
ORIC vs ZLAB: Fundamental Ratings
ORIC
ZLAB
OUTLOOK RATING
1..100
1968
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
3951
P/E GROWTH RATING
1..100
7650
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZLAB's Valuation (15) in the Biotechnology industry is in the same range as ORIC (18) in the null industry. This means that ZLAB’s stock grew similarly to ORIC’s over the last 12 months.

ZLAB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORIC (100) in the null industry. This means that ZLAB’s stock grew similarly to ORIC’s over the last 12 months.

ZLAB's SMR Rating (96) in the Biotechnology industry is in the same range as ORIC (97) in the null industry. This means that ZLAB’s stock grew similarly to ORIC’s over the last 12 months.

ORIC's Price Growth Rating (39) in the null industry is in the same range as ZLAB (51) in the Biotechnology industry. This means that ORIC’s stock grew similarly to ZLAB’s over the last 12 months.

ZLAB's P/E Growth Rating (50) in the Biotechnology industry is in the same range as ORIC (76) in the null industry. This means that ZLAB’s stock grew similarly to ORIC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ORICZLAB
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
84%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
81%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ORIC: $13.85 vs. ZLAB: $22.04)
Brand notoriety: ORIC and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ORIC: 124% vs. ZLAB: 130%
Market capitalization -- ORIC: $1.41B vs. ZLAB: $2.47B
ORIC [@Biotechnology] is valued at $1.41B. ZLAB’s [@Biotechnology] market capitalization is $2.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ORIC’s FA Score shows that 1 FA rating(s) are green while ZLAB’s FA Score has 1 green FA rating(s).

  • ORIC’s FA Score: 1 green, 4 red.
  • ZLAB’s FA Score: 1 green, 4 red.
According to our system of comparison, ZLAB is a better buy in the long-term than ORIC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ORIC’s TA Score shows that 5 TA indicator(s) are bullish while ZLAB’s TA Score has 4 bullish TA indicator(s).

  • ORIC’s TA Score: 5 bullish, 5 bearish.
  • ZLAB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ORIC is a better buy in the short-term than ZLAB.

Price Growth

ORIC (@Biotechnology) experienced а +19.50% price change this week, while ZLAB (@Biotechnology) price change was -6.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ORIC is expected to report earnings on Nov 12, 2026.

ZLAB is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ORIC
Daily Signal:
Gain/Loss:
ZLAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ORIC and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORIC has been loosely correlated with REPL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ORIC jumps, then REPL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORIC
1D Price
Change %
ORIC100%
-1.59%
REPL - ORIC
37%
Loosely correlated
+2.30%
TRVI - ORIC
37%
Loosely correlated
+1.33%
RKTO - ORIC
37%
Loosely correlated
+1.39%
WVE - ORIC
36%
Loosely correlated
-0.59%
RCUS - ORIC
35%
Loosely correlated
+1.36%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ORIC. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ORIC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-8.93%
ORIC - ZLAB
34%
Loosely correlated
-1.59%
AMRN - ZLAB
33%
Loosely correlated
+0.78%
ONC - ZLAB
33%
Poorly correlated
-1.08%
VCYT - ZLAB
32%
Poorly correlated
-0.39%
AXON - ZLAB
32%
Poorly correlated
+2.98%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LKQ22.471.09
+5.10%
LKQ Corp
RMBI15.990.46
+2.96%
Richmond Mutual Bancorporation
ROCK39.270.49
+1.26%
Gibraltar Industries
ROST236.672.49
+1.06%
Ross Stores
GNS0.13-0.01
-4.61%
Genius Group Limited